In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Raptor acquires Quinsair from Tripex

Executive Summary

Tripex Pharmaceuticals licensed Raptor Pharmaceutical Corp. exclusive worldwide rights to develop, manufacture, and commercialize twice-daily Quinsair (levofloxacin), an inhaled fluoroquinolone for managing chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register